The global market for hospital infection therapeutics is poised to grow by an impressive USD 3.10 billion within the next five years (from 2022 to 2027), at a compound annual growth rate (CAGR) of approximately 4.98%, as reported by market research firm Technavio. The projected growth has been largely attributed to specific factors, such as special drug designations influencing market expansion.
These pharmaceutical agents, crafted to combat hospital-acquired infections, along with therapeutic options currently in development, have garnered special recognitions from regulatory bodies like the US FDA and the European Medicines Agency (EMA). This is a testament to their proven efficacy. Such designations, including breakthrough and orphan drug statuses, are vital players in market growth.
The report also identifies increased hospital visits as a significant trend fuelling growth. Nevertheless, it highlights the high costs associated with technological advancements as a potential barrier to market expansion.
Technavio’s report provides insights into major industry players, offering detailed profiles of companies like Abbott Laboratories, Bristol Myers Squibb Co., and Johnson and Johnson, amongst others. In an increasingly competitive landscape, companies are analysed based on multiple performance metrics, such as financial performance, strategic growth measures, product innovations, and recent launches.
The geographical classification reveals North America leading growth, accounting for an estimated 36% of the total growth during the forecast period. This surge can be attributed to escalated healthcare spending, increased prevalence of chronic ailments, preference for therapeutics over surgery, heightened research and development focus and an aging population.
By drug type, antibiotics – particularly broad-spectrum antibiotics like amoxicillin and levofloxacin – are predicted to witness significant growth. These drugs, crucial in the battle against hospital-acquired infections, demonstrate efficacy against a broad array of bacteria, making them essential when specific bacteria are resistant to narrow-spectrum drugs. Narrow-spectrum antibiotics, including azithromycin and clindamycin, are targeted at specific bacterial groups.
The entire landscape of hospital infection therapeutics expands beyond antibiotics, though, also involving antiviral drugs, antifungal medications, disinfectants and sterilization equipment, and several other elements.